Leen Kawas on AI's Revolutionary Impact in Drug Testing and Regulatory Compliance: Transforming Biotech's Future Through Intelligent Innovation

Artificial intelligence is redefining every stage of the biotech pipeline—from discovery and development to clinical trials and compliance. Leading this shift is Leen Kawas, Managing General Partner at Propel Bio Partners, whose strategic investments in AI-powered biotech firms offer a compelling lens into the future of innovation in life sciences.

Read the Full Article Here